Genoway (ALGEN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Genoway (ALGEN) has a cash flow conversion efficiency ratio of -0.152x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.80 Million ≈ $-3.27 Million USD) by net assets (€18.39 Million ≈ $21.50 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ALGEN defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Genoway - Cash Flow Conversion Efficiency Trend (2009–2024)
This chart illustrates how Genoway's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Genoway Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genoway ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Industrial Investment Trust Limited
NSE:IITL
|
0.148x |
|
Battalion Oil Corp
NYSE MKT:BATL
|
-1.381x |
|
Synel M.L.L Payway Ltd
TA:SNEL
|
0.021x |
|
Mount Logan Capital Inc. Common Stock
NASDAQ:MLCI
|
-0.362x |
|
TINYBUILD REGSCAT3 DL-001
F:8Z3
|
N/A |
|
Bellavista Resources Ltd
AU:BVR
|
-0.067x |
|
ERREDUE S.P.A.
F:Z9H
|
N/A |
|
Lisata Therapeutics Inc.
NASDAQ:LSTA
|
-0.195x |
Annual Cash Flow Conversion Efficiency for Genoway (2009–2024)
The table below shows the annual cash flow conversion efficiency of Genoway from 2009 to 2024. For the full company profile with market capitalisation and key ratios, see Genoway market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €18.57 Million ≈ $21.72 Million |
€5.38 Million ≈ $6.29 Million |
0.290x | +64.41% |
| 2023-12-31 | €17.38 Million ≈ $20.32 Million |
€3.06 Million ≈ $3.58 Million |
0.176x | +20.96% |
| 2022-12-31 | €16.17 Million ≈ $18.90 Million |
€2.36 Million ≈ $2.75 Million |
0.146x | +477.82% |
| 2021-12-31 | €14.56 Million ≈ $17.02 Million |
€-561.34K ≈ $-656.27K |
-0.039x | -111.14% |
| 2020-12-31 | €9.00 Million ≈ $10.52 Million |
€-164.33K ≈ $-192.11K |
-0.018x | -110.59% |
| 2019-12-31 | €6.84 Million ≈ $8.00 Million |
€1.18 Million ≈ $1.38 Million |
0.172x | +60.68% |
| 2018-12-31 | €7.89 Million ≈ $9.22 Million |
€847.03K ≈ $990.27K |
0.107x | +24.32% |
| 2017-12-31 | €7.19 Million ≈ $8.41 Million |
€620.94K ≈ $725.94K |
0.086x | +150.36% |
| 2016-12-31 | €5.26 Million ≈ $6.15 Million |
€-901.83K ≈ $-1.05 Million |
-0.171x | -194.23% |
| 2015-12-31 | €4.68 Million ≈ $5.47 Million |
€851.08K ≈ $995.00K |
0.182x | +367.50% |
| 2014-12-31 | €5.15 Million ≈ $6.02 Million |
€200.29K ≈ $234.16K |
0.039x | -76.71% |
| 2013-12-31 | €5.10 Million ≈ $5.97 Million |
€852.87K ≈ $997.09K |
0.167x | +147.59% |
| 2012-12-31 | €4.84 Million ≈ $5.66 Million |
€-1.70 Million ≈ $-1.99 Million |
-0.351x | -347.79% |
| 2011-12-31 | €5.23 Million ≈ $6.12 Million |
€741.51K ≈ $866.90K |
0.142x | -28.72% |
| 2010-12-31 | €4.60 Million ≈ $5.37 Million |
€914.07K ≈ $1.07 Million |
0.199x | -57.80% |
| 2009-12-31 | €3.82 Million ≈ $4.47 Million |
€1.80 Million ≈ $2.11 Million |
0.471x | -- |
About Genoway
genOway Société anonyme, a biotechnology company, engages in the development and commercialization of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines… Read more